enGene Holdings Inc. (NASDAQ:ENGN) Shares Purchased by Blue Owl Capital Holdings LP

Blue Owl Capital Holdings LP lifted its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 3.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,159,975 shares of the company's stock after purchasing an additional 101,006 shares during the period. enGene comprises 5.0% of Blue Owl Capital Holdings LP's holdings, making the stock its 8th biggest holding. Blue Owl Capital Holdings LP owned about 7.15% of enGene worth $21,014,000 as of its most recent SEC filing.

Separately, Vontobel Holding Ltd. acquired a new position in shares of enGene in the fourth quarter worth about $69,000. Institutional investors own 64.16% of the company's stock.

enGene Stock Down 0.8 %

NASDAQ ENGN traded down $0.03 during trading on Tuesday, reaching $3.96. The company's stock had a trading volume of 7,598 shares, compared to its average volume of 131,243. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $201.87 million, a PE ratio of -6.82 and a beta of -0.38. The business has a 50-day moving average price of $4.80 and a 200-day moving average price of $6.59. enGene Holdings Inc. has a 1-year low of $3.50 and a 1-year high of $16.62.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. JMP Securities reiterated a "market outperform" rating and issued a $18.00 target price on shares of enGene in a report on Tuesday. HC Wainwright restated a "buy" rating and set a $25.00 price target on shares of enGene in a report on Tuesday, March 11th. Morgan Stanley decreased their price target on shares of enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a report on Tuesday, March 11th. UBS Group cut shares of enGene from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $34.00 to $7.00 in a report on Friday, February 14th. Finally, Piper Sandler initiated coverage on shares of enGene in a report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target for the company. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $23.29.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.